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Abstract
Background: Striking an adequate balance between bleeding risks and prevention of stent thrombosis can
be challenging in the setting of percutaneous coronary intervention (PCI) with drug eluting stents (DES) in
acute myocardial infarction (MI). This is more pronounced in patients treated with both low molecular weight
heparin (LMWH) and dual antiplatelet therapy (DAPT). Prasugrel, a second generation thienopyridine with more
potent platelet inhibition capability, is associated with significant bleeding risks. This risk of bleeding is often
underestimated when prescribing pharmacological agents such as DAPT and LMWH, designed to reduce ischaemic
events following PCI in acute MI. Life-threatening haemorrhagic pericardial and pleural effusions not associated
with access site bleeding are a rare example of such bleeding complications.
Case presentation: We report a case of a Bangladeshi male who developed cardiac tamponade resulting from
haemorrhagic pericardial effusion as well as bilateral pleural effusions, 9 days after PCI with a DES, while on
prasugrel and aspirin. He had presented late with inferior ST elevation myocardial infarction (STEMI), and was
therefore also given enoxaparin initially. Haemorrhagic pericardial and pleural fluid were drained, and the patient
was discharged on DAPT comprising of aspirin and clopidogrel. Following PCI to obtuse marginal, which was done
as a staged procedure 6 months later, he was commenced on ticagrelor instead of clopidogrel. He developed no
further bleeding complications over 1 year of follow up.
Conclusion: Non-access site bleeding such as this, leading to haemorrhagic pericardial and pleural effusions can
be rare and life-threatening. Furthermore, patients with acute coronary syndromes (ACS) have marked variation in
their risk of major bleeding. Since haemorrhagic complications are associated with mortality, maintaining a balance
between the risk of recurrent ischemia and that of bleeding is of paramount importance. The use of validated
bleeding risk scores, careful monitoring of patients on DAPT with LMWH, or a switch over to agents with lesser
risk of bleeding may reduce such complications.
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Background
Patients admitted with acute myocardial infarction (MI)
are at considerable risk of ischemic complications par-
ticularly during the acute phase, warranting aggressive
pharmacological and interventional therapies. A combin-
ation of Dual Antiplatelet therapy (DAPT) and anticoa-
gulation is commonly prescribed, particularly in the
setting of percutaneous coronary intervention (PCI).
However, the same interventions designed to protect
against such ischemic complications are responsible for
the increased likelihood of major bleeding during
hospitalization [1]. Currently, newer generation thieno-
pyridine antiplatelet agents, such as prasugrel are fre-
quently used in combination with aspirin, particularly in
the setting of percutaneous coronary intervention (PCI)
in acute coronary syndromes (ACS) [1]. This is espe-
cially significant with drug eluting stent (DES) implant-
ation, where adequate inhibition of platelet aggregation
is paramount to preventing stent thrombosis. Prasugrel,
an irreversible platelet P2Y12 receptor inhibitor has su-
perior platelet inhibition properties, but is associated
with a greater risk of haemorrhagic manifestations in
comparison to clopidogrel or ticagrelor [2, 3]. We report
the case of cardiac tamponade complicating haemor-
rhagic pericardial effusion in addition to haemorrhagic
pleural effusions in a patient who was concomitantly ad-
ministered aspirin, prasugrel and low molecular weight
heparin (LMWH).
Case presentation
A 50-year-old Bangladeshi male presented with retro-
sternal compressive chest pain for 2 days, associated
with abdominal discomfort and nausea. He was dyslipid-
emic, normotensive, diabetic on Insulin, and a recent
smoker. On admission his pulse was 110 beats/min,
blood pressure was 110/70 mmHg and unremarkable
precordial examination. Respiratory rate was 24 breaths/
min and chest auscultation revealed bi-basal crackles.
Electrocardiography (ECG) showed ST elevation in leads
II, III and aVF. Bedside echocardiogram revealed a left
ventricular (LV) ejection fraction (EF) of 50 % with
hypokinetic basal and mid segments of inferior, infero-
septal and infero-lateral walls. Troponin I was raised at
17.46 ng/ml. NT-Pro BNP was 1673.90 pg/ml. Given the
delayed presentation (~48 h), he was not thrombolysed,
but given loading doses of aspirin (300 mg) and clopido-
grel (600 mg), subcutaneous enoxaparin, anti-anginal
medications and intravenous furosemide.
Coronary angiogram done the same day revealed
totally occluded right coronary artery (RCA) (Fig. 1), sig-
nificantly diseased obtuse marginal (OM) and moder-
ately diseased left anterior descending (LAD) arteries.
PCI to RCA (infarct related artery) was done with a
3.5x38mm DES (XIENCE Xpedition Everolimus Eluting
Coronary Stent System, Abbott Vascular, USA). Distal
Thrombolysis in Myocardial Infarction (TIMI) III flow
was achieved with no immediate complication (Fig. 2).
As he had received a single dose of LWMH 9 h prior to
PCI, he was only given an additional dose of enoxaparin
equivalent to 0.3 mg/kg intravenously at the time of PCI,
in accordance with guideline recommendations [4].
Unfractionated heparin was not used. Staged PCI to OM
was planned for a later date. As he had no contraindica-
tions, he was given a loading dose of 60 mg prasugrel,
which was continued on 10 mg daily, along with aspirin
75 mg twice daily.
Fig. 1 Coronary angiogram showing totally occluded right
coronary artery
Fig. 2 Coronary angiography showing restoration of TIMI III flow
following stent implantation in right coronary artery
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Two days after PCI, a pericardial rub was noted. Lung
auscultation revealed bi-basal crackles and diminished
breath sounds in the lower zones. Mild pericardial
effusion (~5 mm) was seen on echocardiogram. As we
suspected a haemorrhagic effusion, LMWH was discon-
tinued, prasugrel was withheld, and he was switched
back to clopidogrel (75 mg) and reduced dose of aspirin
(75 mg) once daily. He was regularly monitored over the
next few days, both clinically and echocardiographically:
the intensity of the rub gradually diminished, concomi-
tant with increasing pericardial effusion. Serial ECG
showed evidence of gradual reduction of voltage. Nine
days after PCI, he became hypotensive and tachycardic
with jugular venous distension, clinically suggestive of
cardiac tamponade; this was confirmed by echocardiog-
raphy which revealed massive pericardial effusion more
in anterior, apical and lateral regions and features of dia-
stolic collapse of right ventricle (Fig. 3), with further re-
duction of LV EF to 35 %. There was no evidence of left
ventricular free wall rupture (LVFWR). Subsequently, he
also developed acute pulmonary oedema with bilateral
pleural effusions (Fig. 4).
Percutaneous pericardiocentesis was attempted imme-
diately, but as it failed to yield fluid, emergency pericar-
diotomy was done under general anaesthesia: about
400 ml of haemorrhagic fluid was drained by sub-
xiphoid incision. A further 300 ml of blood and 250 ml
of clots were evacuated 2 h later through previous subxi-
phoid incision, by finger dissection from the pericardial
cavity, mainly around the RA and RV; a retropericardial
drain tube was left in situ, and removed 2 days later.
Laboratory examination of the pericardial fluid demon-
strated haematocrit value of 40 %, similar to that of per-
ipheral venous blood. Given that the pericardiocentesis
was a life-saving procedure that needed to be done on
an emergency basis, we proceeded to do so while the pa-
tient was still on DAPT, which alternatively, could not
be discontinued owing to the impending risk of stent
thrombosis.
Post procedure, the central venous pressure reduced
to 10cmH20, with improved haemodynamic parameters,
and he was extubated the same evening. Following
drainage, echocardiography revealed improved EF of
50 % and effusion was reduced to minimal. As his
haemoglobin had fallen from 12.9 g/dL to 8.2 g/dl, he
was transfused two units of whole blood.
As he remained in acute pulmonary oedema with
bilateral pleural effusions, 700 ml of haemorrhagic
pleural fluid was aspirated from the left pleural cavity
2 days after pericardial fluid drainage and sent for in-
vestigations: pleural fluid protein was 26 mg/dL, LDH
raised at 542U/L. ADA was within normal limit, and
cytology showed plenty of red blood cells, lympho-
cytes, histiocytes and mesothelial cells in a protein-
aceous background, but no malignant cells. Broad-
spectrum intravenous antibiotics were given and he
remained afebrile throughout.
Fig. 3 Echocardiography showing massive pericardial effusion with features of diastolic collapse of right ventricle. (a) RV in systole (b) RV in
diastole (c) effusion measured at 18 mm, 20 mm, 14 mm surrounding the heart
Fig. 4 Chest X ray anterior-posterior view (bedside) showing cardio-
megaly with evidence of pulmonary oedema and bilateral
pleural effusions
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Following the resolution of both pericardial and
pleural effusions, he was discharged 1 week after pericar-
diotomy, with stable haemodynamic parameters on
DAPT comprising of Aspirin (75 mg) and clopidogrel
(75 mg) daily, in addition to diuretics and anti-ischaemic
medication. He underwent successful staged PCI to OM
6 months later, at which time a check angiography of
the left system revealed mild in-stent restenosis of the
RCA stent, which was treated with a balloon angioplasty
with satisfactory result. Subsequently, he was given
DAPT comprising of Aspirin 75 mg daily and ticagre-
lor 90 mg twice daily. He remained well at 1 year of
follow up with no further effusions, as confirmed by
echocardiography.
Discussion
Pericardial effusions are found in 15 to 28 % of patients
presenting with a 1st myocardial infarction. [5–8] They
are more common in patients with anterior STEMI,
larger infarcts and in the presence of congestive heart
failure [5, 8, 9]. It usually appears during the initial
5 days, disappearing slowly over during several weeks to
months [6]. Two-thirds of those patients with moderate-
to-severe effusions develop tamponade or left ventricular
free wall rupture (LVFWR) [10, 11].
Haemorrhagic pericardial effusion and cardiac tam-
ponade in the setting of Acute MI and PCI in this pa-
tient may have arisen due to three principal causes:
coronary artery perforation during PCI, haemorrhagic
pericarditis, and cardiac rupture, most often LVFWR.
The frequency of iatrogenic coronary perforations has
increased over the years, with the advent of new percu-
taneous revascularization techniques and greater inci-
dence of PCI [9, 10]. They are usually associated with
guide wire trauma or catheter manipulation of athero-
sclerotic vessel segments during PCI [9, 10].
In our case, a review of the angiographic images from
various planes both during and after completion of the
procedure, as well as a retrospectively after the effusion
developed, showed no angiographic evidence of perfor-
ation, i.e. an extraluminal crater, contrast extravasation
or cavity spilling after stenting. Moreover, it is Ellis Type
III perforation (defined as extravasation through frank
(>1 mm) perforation) that is associated with the rapid
development of cardiac tamponade (42.9 %) [9], which
would usually have been immediately evident during
procedure. Furthermore, frank perforation leading to
haemorrhagic pericardial effusion and cardiovascular
collapse is usually known to occur as early as 24 h after
PCI [9, 10, 12, 13], whereas cardiac tamponade in our
patient developed approximately 8 days after PCI and
only after the commencement of prasugrel. Neverthe-
less, a small perforation, not visible initially, cannot be
completely excluded; it may have begun to leak seriously
following the onset of action of prasugrel, eventually
resulting in the large haemorrhagic pericardial effusion.
Previously, there have been cases described in the lit-
erature of tamponade arising from haemorrhagic peri-
carditis associated with thrombolysis, usually associated
with anterior MI [14] and more recently with the use of
glycoprotein IIb/IIIa inhibitors during PCI [13, 15] and
combinations thereof [16]. However, few cases of tam-
ponade attributed to prasugrel-induced haemorrhagic ef-
fusions have been reported in the literature.
Prasugrel, an irreversible P2Y12 receptor blocker,
when given in the background of PCI, has been associ-
ated with significantly reduced rates of ischaemic events
i.e. nonfatal MI & stent thrombosis; however, these ben-
efits were limited by higher rates of TIMI major bleeding
(2.2 %), both life-threatening (1.3 %) & fatal bleeding
(0.3 %) as compared to clopidogrel (0.8 and 0.1 % re-
spectively) [2].
Alternatively, clopidogrel resistance is an important
issue that needs to be considered when prescribing anti-
platelet agents post-PCI in Bangladeshi subjects. A pion-
eer study conducted in our centre using the VerifyNow ®
system found that nearly half (46.7 %) of the patients in
the clopidogrel group were resistant to the drug as op-
posed to none in the prasugrel group [17]. Moreover,
guidelines recommend that a loading dose of 325 mg of
non-enteric aspirin be given prior to PCI [4]. Non-enteric
aspirin is not commercially available in Bangladesh; enteric
aspirin has been attributed as a cause of aspirin resistance,
due to reduced bio-availability from impaired absorption
and inadequate platelet inhibition due to uninhibited plate-
let cyclooxygenase activity [18, 19]. For this reason, when
prescribed with clopidogrel, our centre follows a practice of
an initial maintenance dose of aspirin 75 mg twice daily,
followed by a reduction to 75 mg daily later on.
The CRUSADE Bleeding Score calculated for this pa-
tient was 26, corresponding to an estimated low risk of
bleeding, and a 6.3 % estimated risk of in-hospital major
bleeding [20]. This patient’s calculated ACUITY-
HORIZONS-AMI Integer-Based Risk Score was 11, cor-
responding to a moderate category with a 3.3 % risk of
Non–coronary artery bypass graft (CABG)-Related
Major Bleeding Within 30 days of Patient Presentation
with ACS [21]. Clinical trial data show that complica-
tions with prasugrel were more frequent in specified
high risk subgroups (age >75 years, previous stroke/
transient ischaemic attack (TIA), body weight <60 kg),
none of which our patient had [2].
Thus, given this relative lower pre-procedural bleeding
risk, and absence of contraindications such as prior
stroke or TIA, we opted for prasugrel as per guidelines,
once the coronary anatomy was known and PCI to
infarct-related artery was planned [1]. Our patient was
initially given a clopidogrel load as part of guideline-
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recommended antiplatelet therapy in ACS prior to PCI;
a further rationale for this strategy was that, should the
angiography reveal coronary artery disease requiring
CABG, clopidogrel need only be stopped 5 days or lesser
before CABG, as opposed to prasugrel, whose duration
of action is longer, requiring it to be withheld 7 days
before CABG. Moreover, off pump CABG may be
considered within 24 h of clopidogrel or ticagrelor
administration [1].
In clinical practice, most bleeding complications ob-
served have been minor and related to the angiographic
access site leading to haematoma or mucosal bleeding in
the form of epistaxis or gum bleeding. Although prasu-
grel has been known to increase bleeding complications
[2], the association with haemorrhagic pericardial
effusion leading to tamponade has been rarely reported.
However, the administration of a loading dose of prasu-
grel following the previous loading dose of clopidogrel
could be an additional factor for excess bleeding, al-
though such a complication has not been observed pre-
viously in our centre.
Kaul et al. who conducted a multicentric, hospital
registry in India of 1000 patients with ACS undergoing
PCI who were administered prasugrel found only one
patient who developed hemorrhagic pericardial effusion
following 2 days post PCI which required surgical
drainage for resulting tamponade [21]. This patient had
undergone delayed angioplasty following a STEMI, just
like our case. This also poses a possible association of
haemorrhagic infarction and subsequent haemorrhagic
pericarditis due to late reperfusion therapy which may
be considered [13], as symptom onset to balloon time
was nearly 60 h in our case, owing to delayed presenta-
tion. In fact, among the predictors of cardiac tamponade
in STEMI patients are lack of reperfusion therapy and
late hospital admission [22], both of which corresponds
with our patient, the other factors being lateral site, in-
creasing age and increasing number of leads involved
[22]. This compounded by the potent anti-platelet prop-
erties of prasugrel and as such, the excessive bleeding
tendency was the most likely mechanism for this devas-
tating complication. Dressler’s syndrome which usually
presents with fever, pleuro-pericardial discomfort,
friction rub, leucocytosis, raised ESR and pulmonary in-
filtrates typically presents weeks to months after acute
MI, is recurrent and causes a fibrinous pericarditis [2,
23]. Although the timing of effusions in our patients is
slightly earlier than those described for Dressler’s
syndrome, the possibility of an inflammatory process
should be considered, which may have eventually led to
haemorrhagic effusions, owing to the effect of the strong
antiplatelet action.
Our patient was also administered LMWH, which was
discontinued as soon as the mild effusion was noted.
Combination of LWMH with prasugrel could be associ-
ated with increased bleeding risks. As such, detection of
pericardial effusion >1 cm on echocardiography or
enlarging pericardial effusion is an indication for dis-
continuation of anticoagulation unless continuation is
strongly indicated, in which case heightened monitor-
ing and observation for signs of possible tamponade
is mandatory [2].
Cardiac rupture, particularly LVFWR following acute
MI may lead to haemopericardium and cardiac tampon-
ade [24, 25], albeit associated with reduced incidence
following revasularisation. Among the two distinct types
(i.e. acute (blowout type) and subacute (oozing) type)
[25], the subacute free wall rupture may evolve over
hours or even days, and presents initially with pericardial
effusion-related signs and symptoms [26]. However, this
usually occurs 1 to 3 days following acute MI [16], the
timing of which is inconsistent with the time course of
our patient’s illness. Furthermore, LVFWR can be easily
diagnosed echocardiographically by the demonstration
of myocardial tear in the LV free wall, low-velocity
colour Doppler flow or extravasation of intravenous
echocardiographic contrast from LV cavity into the effu-
sion [27], none of which was evident in our patient.
Thus the hypothesis that could explain cardiac tam-
ponade in our patient, in the presence of inferior STEMI
implies the association of increased bleeding risks with
combined LWMH and DAPT comprising of prasugrel
and aspirin. This aetiological association is further sup-
ported by the finding of concomitant heart failure and
haemorrhagic pleural effusions requiring drainage. Heart
failure is known to complicate 49 % of infarctions with
pericardial involvement as opposed to 16 % of infarc-
tions without effusion (p < 0.01) [3].
This patient developed these life-threatening bleeding
complications despite having no contraindication to pra-
sugrel in terms of age, body weight or previous bleeding
episodes/stroke. It was also not associated with any
‘warning bleed’ in the form of mucosal of access site
haematoma.
Achieving the correct balance between adequate inhib-
ition of platelet aggregation and preventing stent throm-
bosis on one hand, and the prevention of adverse
bleeding outcomes on the other hand, remains a challen-
ging dilemma in the PCI era. The use of validated risk
scores for bleeding such as the CRUSADE risk score and
the ACUITY-HORIZONS bleeding risk score may be
helpful for stratifying and thus identifying patients at
increased risk of bleeding complications, and guide
the appropriate choice of pharmacotherapy [20, 28].
Furthermore, careful monitoring for potential bleed-
ing risks is imperative when LMWH and DAPT
comprising prasugrel is co-administered. This issue
is underscored by the fact that complete cessation of
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antiplatelet drugs could not be afforded at any cost
as the patient had already undergone PCI and risked
stent thrombosis in that event. Our only option
therefore was to switch over to clopidogrel at a
lower dose in addition to aspirin, despite the add-
itional issue of clopidogrel resistance in Bangladeshi
subjects. Following staged PCI to OM which was
done 6 months later, he was started on ticagrelor,
which, according to the PLATO trial, has demon-
strated improved CV outcomes in comparison to
clopidogrel, with no significant difference in the
rates of major bleeding similar safety profile with
regards to major bleeding, albeit a higher rate of
non-CABG related major bleeding (4.5 % for ticagre-
lor vs. 3.8 % for clopidogrel, P = 0.03) [3].
Pericardial effusion can be easily detected by echocar-
diography and as such close monitoring and routine
echocardiographic evaluation of these patients can lead
to early detection of a minimal PE and subsequent alter-
ation of drug dosage or switch over to antiplatelet agents
of lesser bleeding risk is possible. This case report is a
demonstration of how the risk of bleeding in patients is
often underestimated, and the need for clinicians to be
wary of the ominous signs of life-threatening bleeds oc-
curring due to pharmacotherapy. In addition to strat-
egies for reducing haemorrhagic complications such as
the use of newer antithrombotic medications with re-
duced potential for bleeding and avoidance of overdos-
ing, it is important to identifying patients at risk for
major bleeding events by means of risk scores, and pre-
scribe medication accordingly.
Conclusion
Haemorrhagic complications are an independent risk
factor for mortality in patients with ACS and in those
undergoing PCI. Patients with ACS have marked vari-
ation in their risk of major bleeding. Emphasis is placed
on the fact that despite the efficacy of combination ther-
apies comprising antiplatelet agents and anticoagulants
in the prevention and treatment of adverse events of
coronary interventions in the setting of acute MI, careful
monitoring for haemorrhagic complications is para-
mount. Routine evaluation of patients at risk for exces-
sive bleeding by means of bleeding risk scores are
recommended. A cessation of the offending agent or
switch over to drugs with lesser bleeding risks may be
warranted.
Acknowledgements
The staff at the cardiac catheterisation laboratory and department of surgery
of Ibrahim Cardiac Hospital & Research Institute, Dhaka, Bangladesh.
Funding
Funding was not required for this case report.
Availability of data and materials
Not applicable. All data pertaining to the case report have been included in
the document submitted.
Authors’ contributions
FAC and MMH were responsible for original manuscript design and draft
and the acquisition of data. FAC, MMH, SN and MRK were involved in direct
patient care and emergency catheterization laboratory intervention. FAC,
MRK and SN were involved in post-catheterisation patient management.
MMH was involved in revision of the manuscript for important intellectual
content. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent for the publication was obtained from the
patient for publication of this case report and any accompanying
images. A copy of the written consent is available for review by the
Editor-in-Chief of this journal.
Ethics approval and consent to participate
The publication of this case report was approved by the ethics committee of
Ibrahim Cardiac Hospital & Research Institute (ICHRI), Dhaka, Bangladesh.
Received: 19 March 2016 Accepted: 1 July 2016
References
1. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the
management of ST-elevation myocardial infarction: executive summary: a
report of the American college of cardiology foundation/American heart
association task force on practice guidelines: developed in collaboration
with the American college of emergency physicians and society for
cardiovascular angiography and interventions. Catheter Cardiovasc Interv.
2013;82(1):E1–27.
2. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,
et al. TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N
Engl J Med. 2009;361(11):1045–57.
4. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B,
et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary
intervention: a report of the American college of cardiology
foundation/American heart association task force on practice
guidelines and the society for cardiovascular angiography and
interventions. Circulation. 2011;124(23):e574–651.
5. Mega JL, Morrow DA. ST elevation myocardial infarction: management. In:
Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald’s heart disease:
a textbook of cardiovascular medicine. 10th ed. Philadelphia: Elsevier
Saunders; 2015. p. 1095–54.
6. Widimský P, Gregor P. Pericardial involvement during the course of
myocardial infarction. A long-term clinical and echocardiographic study.
Chest. 1995;108(1):89–93.
7. Nemeth MA, Coulter S, Flamm SD. Pericarditis after myocardial infarction.
Tex Heart Inst J. 2003;30(3):246–47.
8. Galve E, Garcia-Del-Castillo H, Evangelista A, Batlle J, Permanyer-Miralda
G, Soler-Soler J. Pericardial effusion in the course of myocardial
infarction: incidence, natural history, and clinical relevance. Circulation.
1986;73(2):294–49.
9. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new
device era. Incidence, classification, management, and outcome. Circulation.
1994;90(6):2725–30.
10. Rogers JH, Lasala JM. Coronary artery dissection and perforation
complicating percutaneous coronary intervention. J Invasive Cardiol. 2004;
16(9):493–39.
11. Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and
progression of pericardial effusion in patients with a first myocardial
infarction: relationship to age and free wall rupture. Am Heart J. 2002;
144(2):251–58.
Cader et al. BMC Cardiovascular Disorders  (2016) 16:162 Page 6 of 7
12. Ajluni SC, Glazier S, Blankenship L, et al. Perforations after percutaneous
coronary interventions: clinical, angiographic, and therapeutic observations.
Cathet Cardiovasc Diagn. 1994;32(3):206–12.
13. Kim SS, Jeong MH, Sim DS, et al. Sequential development of cardiac
tamponade and subacute stent thrombosis after primary percutaneous
coronary intervention for acute ST-segment elevation myocardial infarction:
a case report. J Cardiol Case. 2010;1(2):e75–9.
14. Renkin J, Bruyne BD, Benit E, Joris J-M, Carlier M, Col J. Cardiac tamponade
early after thrombolysis for acute myocardial infarction : a rare but Not
reported hemorrhagic complication. J Am CoL Cardiol. 1991;17(1):280–85.
15. Moon S-J, Yoon H-J, Her S-H, et al. Hemorrhagic pericarditis with cardiac
tamponade after percutaneous coronary intervention associated with the
use of abciximab. Korean J Intern Med. 2008;23(3):156–60.
16. Psychari SN, Kolettis TM, Apostolou TS. Hemorrhagic pericarditis as a
complication of combined thrombolytic, antiplatelet and anticoagulant
treatment. Hellenic J Cardiol. 2002;43:166–69.
17. Haq MM, Ahsan CH, Amin MN, Karim MR, Ali ML, Khan SR, et al. Comparison
of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients
undergoing percutaneous coronary intervention. Bangladesh Med Res
Counc Bull. 2013;39(3):139–45.
18. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet
response to low-dose enteric-coated aspirin in patients with stable
cardiovascular disease. J Am Coll Cardiol. 2005;46(7):1258–63.
19. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of
enteric coating on antiplatelet activity of low-dose aspirin in healthy
volunteers. Stroke. 2006;37(8):2153–58.
20. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A
risk score to predict bleeding in patients with acute coronary syndromes. J
Am Coll Cardiol. 2010;55(23):2556–66.
21. Kaul U, Sethi A, Arambam P, et al. Safety of Prasugrel in Indian patients -
multicentric registry of 1000 cases. Indian Heart J. 2014;66(6):598–601.
22. Figueras J, Barrabés JA, Lidón RM, Sambola A, Bañeras J, Palomares JR, et al.
Predictors of moderate-to-severe pericardial effusion, cardiac tamponade,
and electromechanical dissociation in patients with ST-elevation myocardial
infarction. Am J Cardiol. 2014;113(8):1291–96.
23. Yazdani SK, Ladich E, Virmani R. Pathology of myocardial ischaemia,
infarction, reperfusion, and sudden death. In: Fuster V, Walsh RA,
Harrington RA, editors. Hurst’s the heart. 13th ed. New York: McGraw
Hill Medical; 2011. p. 1296–315.
24. Stryjer D, Friedrensohn A, Hendler A. Myocardial rupture in acute
myocardial infarction: urgent management. Br Heart J. 1988;59:73–4.
25. Pollac H, Diez W, Spiel R, Enenkel W, Mlczoch J. Early diagnosis of
subacute free wall rupture complication acute myocardial infarction.
Eur Heart J. 1993;14:640–48.
26. Purcaro A, Costantini C, Ciampani N, et al. Diagnostic criteria and
management of subacute ventricular free wall rupture complicating acute
myocardial infarction. Am J Cardiol. 1997;80:397–405.
27. Solomon SD, Wu J, Gillam L. Echocardiography. In: Mann DL, Zipes DP,
Libby P, Bonow RO, editors. Braunwald’s heart disease: a textbook of
cardiovascular medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015.
p. 179–270.
28. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline
risk of major bleeding in non-ST-segment-elevation myocardial infarction:
the CRUSADE (Can rapid risk stratification of unstable angina patients
suppress ADverse outcomes with early implementation of the ACC/AHA
guidelines) bleeding score. Circulation. 2009;119(14):1873–82.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Cader et al. BMC Cardiovascular Disorders  (2016) 16:162 Page 7 of 7
